Agid O - Search Results

1

Incentive motivation deficits in schizophrenia reflect effort computation impairments during cost-benefit decision-making.

Fervaha G, Graff-Guerrero A, Zakzanis KK, Foussias G, Agid O, Remington G. Fervaha G, et al. Among authors: agid o. J Psychiatr Res. 2013 Nov;47(11):1590-6. doi: 10.1016/j.jpsychires.2013.08.003. Epub 2013 Aug 28. J Psychiatr Res. 2013. PMID: 23992770

2

Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics.

Tauscher J, Hussain T, Agid O, Verhoeff NP, Wilson AA, Houle S, Remington G, Zipursky RB, Kapur S. Tauscher J, et al. Among authors: agid o. Am J Psychiatry. 2004 Sep;161(9):1620-5. doi: 10.1176/appi.ajp.161.9.1620. Am J Psychiatry. 2004. PMID: 15337652

3

Early use of clozapine for poorly responding first-episode psychosis.

Agid O, Remington G, Kapur S, Arenovich T, Zipursky RB. Agid O, et al. J Clin Psychopharmacol. 2007 Aug;27(4):369-73. doi: 10.1097/jcp.0b013e3180d0a6d4. J Clin Psychopharmacol. 2007. PMID: 17632221

4

Emerging drugs for schizophrenia.

Agid O, Kapur S, Remington G. Agid O, et al. Expert Opin Emerg Drugs. 2008 Sep;13(3):479-95. doi: 10.1517/14728214.13.3.479. Expert Opin Emerg Drugs. 2008. PMID: 18764724 Review.

5

The dopamine D2 receptors in high-affinity state and D3 receptors in schizophrenia: a clinical [11C]-(+)-PHNO PET study.

Graff-Guerrero A, Mizrahi R, Agid O, Marcon H, Barsoum P, Rusjan P, Wilson AA, Zipursky R, Kapur S. Graff-Guerrero A, et al. Among authors: agid o. Neuropsychopharmacology. 2009 Mar;34(4):1078-86. doi: 10.1038/npp.2008.199. Epub 2008 Nov 5. Neuropsychopharmacology. 2009. PMID: 18987627

6

Progress in defining optimal treatment outcome in schizophrenia.

Remington G, Foussias G, Agid O. Remington G, et al. Among authors: agid o. CNS Drugs. 2010 Jan;24(1):9-20. doi: 10.2165/11530250-000000000-00000. CNS Drugs. 2010. PMID: 20030416 Review.

7

Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention.

Agid O, Foussias G, Remington G. Agid O, et al. Expert Opin Pharmacother. 2010 Oct;11(14):2301-17. doi: 10.1517/14656566.2010.499125. Expert Opin Pharmacother. 2010. PMID: 20586707 Review.

8

Where to position clozapine: re-examining the evidence.

Agid O, Foussias G, Singh S, Remington G. Agid O, et al. Can J Psychiatry. 2010 Oct;55(10):677-84. doi: 10.1177/070674371005501007. Can J Psychiatry. 2010. PMID: 20964947 Review.

9

An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis.

Agid O, Arenovich T, Sajeev G, Zipursky RB, Kapur S, Foussias G, Remington G. Agid O, et al. J Clin Psychiatry. 2011 Nov;72(11):1439-44. doi: 10.4088/JCP.09m05785yel. Epub 2011 Mar 8. J Clin Psychiatry. 2011. PMID: 21457676 Clinical Trial.

10

Schizophrenia as a disorder of too little dopamine: implications for symptoms and treatment.

Remington G, Agid O, Foussias G. Remington G, et al. Among authors: agid o. Expert Rev Neurother. 2011 Apr;11(4):589-607. doi: 10.1586/ern.10.191. Expert Rev Neurother. 2011. PMID: 21469931 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

136 results

Search Page

Filters